<HashMap><database>GEO</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Other>ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE336nnn/GSE336731/</Other></files><type>primary</type></body><statusCodeValue>200</statusCodeValue><statusCode>OK</statusCode></file_versions><scores/><additional><omics_type>Transcriptomics</omics_type><species>Homo sapiens</species><gds_type>Expression profiling by high throughput sequencing</gds_type><full_dataset_link>https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE336731</full_dataset_link><repository>GEO</repository><entry_type>GSE</entry_type></additional><is_claimable>false</is_claimable><name>Transcriptomic profiling of MCF7 ESR1-PARENT and ESR1-Y537S cells cultured under estrogen-depleted or estradiol-supplemented conditions following abemaciclib treatment and CCND1 knockdown</name><description>The retinoblastoma protein (Rb) is a tumour suppressor best known for repressing E2F transcription factors and halting cell cycle progression. In hormone receptor-positive (HR+) breast cancer, CDK4/6 inhibitors activate Rb by preventing its phosphorylation, forming a key component of current endocrine therapy regimens. How pharmacologically activated Rb remodels chromatin and influences transcription beyond cell cycle arrest remains poorly understood. Here we show that CDK4/6 inhibition induces redistribution of hypo-phosphorylated Rb to promoters and enhancers. While Rb predictably binds to cell cycle gene promoters to repress transcription, at other sites it unexpectedly promotes expression of oestrogen-responsive genes by integrating into oestrogen receptor (ER)-rich transcriptional hubs. CDK4/6 inhibition enhances ER target gene expression in breast cancer cells, patient-derived xenografts, and clinical HR+ breast cancer samples in an Rb-dependent manner. This reprogramming is mediated in part by KDM5A, whose interaction with Rb contributes to gene regulation at these loci. Critically, components of this Rb-driven ER transcriptional program are pro-proliferative. In endocrine-sensitive tumours, this can be neutralised with anti-oestrogen therapy, explaining therapeutic synergy. In endocrine-resistant settings such as ESR1-mutant breast cancer, the program persists, limiting therapeutic efficacy. These findings reframe Rb as a dual-function transcriptional regulator that, while enforcing cell cycle arrest, can also activate programs that counteract its tumour suppressor function.</description><dates><publication>2026/06/29</publication></dates><accession>GSE336731</accession><cross_references><GSM>GSM9841480</GSM><GSM>GSM9841503</GSM><GSM>GSM9841469</GSM><GSM>GSM9841502</GSM><GSM>GSM9841501</GSM><GSM>GSM9841468</GSM><GSM>GSM9841489</GSM><GSM>GSM9841500</GSM><GSM>GSM9841488</GSM><GSM>GSM9841487</GSM><GSM>GSM9841486</GSM><GSM>GSM9841485</GSM><GSM>GSM9841484</GSM><GSM>GSM9841483</GSM><GSM>GSM9841482</GSM><GSM>GSM9841481</GSM><GSM>GSM9841491</GSM><GSM>GSM9841490</GSM><GSM>GSM9841479</GSM><GSM>GSM9841478</GSM><GSM>GSM9841477</GSM><GSM>GSM9841499</GSM><GSM>GSM9841498</GSM><GSM>GSM9841476</GSM><GSM>GSM9841497</GSM><GSM>GSM9841475</GSM><GSM>GSM9841496</GSM><GSM>GSM9841474</GSM><GSM>GSM9841495</GSM><GSM>GSM9841473</GSM><GSM>GSM9841472</GSM><GSM>GSM9841494</GSM><GSM>GSM9841493</GSM><GSM>GSM9841471</GSM><GSM>GSM9841492</GSM><GSM>GSM9841470</GSM><GPL>18573</GPL><GSE>336731</GSE><taxon>Homo sapiens</taxon></cross_references></HashMap>